Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

BACKGROUND: Data on efficacy of bevacizumab (B) beyond first-line taxane -including regimen (BT) as first-line treatment are lacking. Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance...

詳細記述

保存先:
書誌詳細
主要な著者: Fabi, Alessandra, Russillo, Michelangelo, Ferretti, Gianluigi, Metro, Giulio, Nisticò, Cecilia, Papaldo, Paola, De Vita, Ferdinando, D’Auria, Giuliana, Vidiri, Antonello, Giannarelli, Diana, Cognetti, Francesco
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2012
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3488474/
https://ncbi.nlm.nih.gov/pubmed/23083011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-482
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料